Updated on 25 June 2013
Post the global slump impacting Asia since 2009, the industry shows signs of promising recovery across geographies. Among the trends to watch out for, will be an upswing in patient benefits and an increased investment in R&D by the companies and of course, market consolidation will continue.
The number of billion dollar companies is swelling in Asia Pacific. Moreover, the private companies' scenario continues to remain vibrant, aided by governments' support in terms of infrastructure, grants and funding. The countries to watch out for in the future are Taiwan and Malaysia, where the government has undertaken huge initiatives to improve infrastructure for the bioindustry.
Read in-depth analysis of the life science industry from the follwing countries: